| Use of PER977 to reverse the anticoagulant effect of edoxaban JE Ansell, SH Bakhru, BE Laulicht, SS Steiner, M Grosso, K Brown, ... New England Journal of Medicine 371 (22), 2141-2142, 2014 | 518 | 2014 |
| Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor J Mendell, H Zahir, N Matsushima, R Noveck, F Lee, S Chen, G Zhang, ... American Journal of Cardiovascular Drugs 13, 331-342, 2013 | 255 | 2013 |
| Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee N Babul, R Noveck, H Chipman, SH Roth, T Gana, K Albert Journal of pain and symptom management 28 (1), 59-71, 2004 | 205 | 2004 |
| Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia M Lynn, DP Rossignol, JL Wheeler, RJ Kao, CA Perdomo, R Noveck, ... The Journal of infectious diseases 187 (4), 631-639, 2003 | 195 | 2003 |
| Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban JE Ansell, SH Bakhru, BE Laulicht, SS Steiner, MA Grosso, K Brown, ... Thrombosis and haemostasis 117 (02), 238-245, 2017 | 164 | 2017 |
| Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers KD Wilner, M Rushing, C Walden, R Adler, J Eskra, R Noveck, R Vargas The Journal of Clinical Pharmacology 42 (9), 1027-1030, 2002 | 126 | 2002 |
| Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials RJ Noveck, A Laurent, M Kuss, S Talwalker, RC Hubbard clinical drug investigation 21, 465-476, 2001 | 122 | 2001 |
| Microdosing and drug development: past, present and future G Lappin, R Noveck, T Burt Expert opinion on drug metabolism & toxicology 9 (7), 817-834, 2013 | 108 | 2013 |
| Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers RJ Noveck, EJ Shannon, PT Leese, JS Shorr, KE Flaim, PE Keipert, ... Anesthesia & Analgesia 91 (4), 812-822, 2000 | 106 | 2000 |
| Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers PT Leese, RJ Noveck, JS Shorr, CM Woods, KE Flaim, PE Keipert Anesthesia & Analgesia 91 (4), 804-811, 2000 | 100 | 2000 |
| Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily RZ Harris, D Padhi, TC Marbury, RJ Noveck, M Salfi, JT Sullivan American journal of kidney diseases 44 (6), 1070-1076, 2004 | 83 | 2004 |
| Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate WB White, GA Mansoor, TG Pickering, DG Vidt, HG Hutchinson, ... American journal of hypertension 12 (8), 806-814, 1999 | 83 | 1999 |
| Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers WA Andes, RJ Noveck, JS Fleming Thrombosis and haemostasis 52 (06), 325-328, 1984 | 78 | 1984 |
| Dose‐proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled‐release oral delivery system NB Modi, B Wang, RJ Noveck, SK Gupta The Journal of Clinical Pharmacology 40 (10), 1141-1149, 2000 | 73 | 2000 |
| Percutaneous Absorption and Pharmacokinetics of Eflornithine HC® l 13.9% Cream in Women with Unwanted Facial Hair B Malhotra, R Noveck, D Behr, M Palmisano The Journal of Clinical Pharmacology 41 (9), 972-978, 2001 | 67 | 2001 |
| Dose-ranging analgesic study of prosorb® diclofenac potassium in postsurgical dental pain EV Hersh, LM Levin, D Adamson, S Christensen, TA Kiersch, R Noveck, ... Clinical therapeutics 26 (8), 1215-1227, 2004 | 64 | 2004 |
| Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination J Mendell, RJ Noveck, M Shi Journal of cardiovascular pharmacology, 2022 | 58 | 2022 |
| Human endotoxin administration as an experimental model in drug development AF Suffredini, RJ Noveck Clinical Pharmacology & Therapeutics 96 (4), 418-422, 2014 | 54 | 2014 |
| Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia M Lynn, YN Wong, JL Wheeler, RJ Kao, CA Perdomo, R Noveck, ... Journal of Pharmacology and Experimental Therapeutics 308 (1), 175-181, 2004 | 53 | 2004 |
| A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin J Mendell, RJ Noveck, M Shi British journal of clinical pharmacology 75 (4), 966-978, 2013 | 49 | 2013 |
